STOCK TITAN

Clearside Biomedical Inc - CLSD STOCK NEWS

Welcome to our dedicated news page for Clearside Biomedical (Ticker: CLSD), a resource for investors and traders seeking the latest updates and insights on Clearside Biomedical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Clearside Biomedical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Clearside Biomedical's position in the market.

Rhea-AI Summary
Clearside Biomedical, Inc. announced a registered direct offering of 11,111,111 shares of common stock and accompanying warrants to purchase the same number of shares. The offer price for one share and accompanying warrant is $1.35, with the warrants having an exercise price of $1.62 per share. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
offering
-
Rhea-AI Summary
Clearside Biomedical, Inc. (Nasdaq: CLSD) completes randomization in ODYSSEY Phase 2b clinical trial for CLS-AX in neovascular age-related macular degeneration (wet AMD), with topline data expected in Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
Clearside Biomedical, Inc. (Nasdaq: CLSD) expands its proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor through a new licensing partnership with BioCryst Pharmaceuticals. The collaboration includes $5 million upfront and the potential for additional $77.5 million in milestone payments, plus royalties. Recruitment for the CLS-AX Phase 2b ODYSSEY Wet AMD Trial is completed, with topline data expected in Q3 2024. The company's President and CEO, George Lasezkay, highlighted the strategic advancements in the internal pipeline and external collaborations, emphasizing the potential of the partnership with BioCryst to target diabetic macular edema (DME) utilizing suprachoroidal administration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
earnings
Rhea-AI Summary
Clearside Biomedical, Inc. (CLSD) to participate in fireside chat at Stifel 2023 Healthcare Conference. CEO George Lasezkay to speak on November 15, 2023, at 8:35 a.m. ET in New York, NY. The webcast will be available on the Clearside website under the Investors section.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.65%
Tags
conferences
-
Rhea-AI Summary
Clearside Biomedical, Inc. (Nasdaq: CLSD) presents encouraging safety and efficacy data at AAO Annual Meeting, highlighting SCS Microinjector's role in treating retinal diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.65%
Tags
clinical trial
-
Rhea-AI Summary
Clearside Biomedical, Inc. announced that multiple oral and poster presentations featuring clinical data utilizing their Suprachoroidal Delivery Technology will be delivered at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting. The presentations will cover various studies on different therapies for eye diseases such as nAMD, uveitic macular edema, diabetic retinopathy, and choroidal melanoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.85%
Tags
none
Rhea-AI Summary
Clearside Biomedical, Inc. has successfully completed recruitment for its ODYSSEY Phase 2b clinical trial. The trial is evaluating the safety and efficacy of CLS-AX, a tyrosine kinase inhibitor for neovascular age-related macular degeneration. Topline data is expected in Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.24%
Tags
clinical trial
-
Rhea-AI Summary
Clearside Biomedical, Inc. (Nasdaq: CLSD) will report its third quarter 2023 financial results on November 13, 2023. A webcast and conference call will be held at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Participants can access the webcast on the Clearside website and join the call by dialing the provided numbers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.22%
Tags
conferences earnings
-
Rhea-AI Summary
Clearside Biomedical announces completion of enrollment in Phase 3 clinical trial for ARCATUS in China, positive progress for suprachoroidal delivery platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
clinical trial
Rhea-AI Summary
Clearside Biomedical CFO to participate in panel discussion at JonesTrading Healthcare Summit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
conferences
Clearside Biomedical Inc

Nasdaq:CLSD

CLSD Rankings

CLSD Stock Data

96.39M
57.86M
7.1%
21.21%
0.29%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Alpharetta

About CLSD

clearside biomedical, inc. is a pharmaceuticals company located in 1220 old alpharetta rd., suite 300, alpharetta, ga, united states.